NextPlat (NXPL) Accumulated Expenses (2016 - 2026)
NextPlat's (NXPL) quarterly Accumulated Expenses came in at $1.8 million in Q2 2026, up 741.35% year-over-year from $208000.0 in Q2 2025, and little changed quarter-over-quarter from $1.8 million in Q4 2025.
Analysis
NextPlat (NXPL) Accumulated Expenses (2016 - 2026) Analysis & Trends
NextPlat (NXPL) has reported Accumulated Expenses for 10 consecutive years, with $1.8 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Accumulated Expenses rose 741.35% year-over-year to $1.8 million in Q2 2026; TTM through Jun 2026 was $1.8 million, a 741.35% increase from a year earlier, with the FY2025 full-year figure at $1.8 million, up 550.56% from the prior year.
- Accumulated Expenses was $1.8 million for Q2 2026 at NextPlat, roughly flat from $1.8 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $1.8 million in Q4 2025 and troughed at $17389.0 in Q2 2022.
- A 5-year average of $383293.2 and a median of $208000.0 in 2025 frame the typical range for Accumulated Expenses.
- The widest YoY moves for Accumulated Expenses: up 16515.94% in 2022, down 85.69% in 2022.
- Over 5 years, Accumulated Expenses stood at $23000.0 in 2022, then surged by 769.57% to $200000.0 in 2023, then jumped by 34.5% to $269000.0 in 2024, then surged by 550.56% to $1.8 million in 2025, then changed by 0.0% to $1.8 million in 2026.
- The last three Accumulated Expenses figures came in at $1.8 million (Q2 2026), $1.8 million (Q4 2025), and $378000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.75 Mn |
| Dec 31, 2025 | 1.75 Mn |
| Sep 30, 2025 | 378,000.00 |
| Jun 30, 2025 | 208,000.00 |
| Mar 31, 2025 | 402,000.00 |
| Dec 31, 2024 | 269,000.00 |
| Sep 30, 2024 | 449,000.00 |
| Jun 30, 2024 | 199,000.00 |
| Mar 31, 2024 | 378,000.00 |
| Dec 31, 2023 | 200,000.00 |
| Sep 30, 2023 | 366,569.00 |
| Jun 30, 2023 | 30,914.00 |
| Mar 31, 2023 | 27,835.00 |
| Dec 31, 2022 | 23,000.00 |
| Sep 30, 2022 | 22,930.00 |
| Jun 30, 2022 | 17,389.00 |
| Mar 31, 2022 | 44,347.00 |
| Dec 31, 2021 | 20,107.00 |
| Sep 30, 2021 | 138.00 |
| Jun 30, 2021 | 121,476.00 |